Home Contact Sitemap

eRAM

encyclopedia of Rare Disease Annotation for Precision Medicine




Disease carcinoma, squamous cell
Comorbidity C0007131|nsclc
Sentences 16
PubMedID- 21718596 [18] reported that egfr mutations were more common in ercc1-negative nsclc patients with squamous cell carcinomas or adenocarcinomas.
PubMedID- 22865300 Methods: hmlh1 and hmsh2 mrna expression was previously evaluated by qpcr for 29 nsclc patients (13 with squamous cell carcinoma [sqc] and 16 with adenocarcinoma [adc]) and mmr mrna levels were converted into clinically distinct phenotypic entities.
PubMedID- 25689063 25 reported that plasma shla-g was exclusively elevated in nsclc, especially in patients with squamous cell carcinoma.
PubMedID- 25789531 Adenocarcinomas and squamous cell carcinomas included with these nsclc could be diagnosed by immunohistochemistry with antibodies against ttf-1, napsin a, cytokeratin (ck)7, p40, p63, and ck5/6 with moderate to good sensitivities and specificities.
PubMedID- 25922640 Of these cases, approximately 85% were categorized as non-small cell lung cancer (nsclc), with squamous cell carcinoma, adenocarcinoma, and large cell carcinoma as the other subtypes [1].
PubMedID- 23211354 Our results suggested that the ercc5 rs751402 aa genotype increased the chemotherapy response in advanced nsclc, especially in patients with squamous cell carcinoma.
PubMedID- 25873045 Participants meeting the following criteria will be included:with histologically or cytologically confirmed stage iiib or iv nsclc with histologic features of adenocarcinoma, squamous cell carcinoma or adenosquamous carcinoma;aged from 18 to 80-years-old;harboring activating egfr mutations (either exon 19 deletion or l858r in exon 21);eastern cooperative oncology group (ecog) performance status score 0 to 2;no previous chemotherapy or biologic or immunologic therapy;measurable lesion according to the response evaluation criteria in solid tumors (recist);adequate organ function;good compliance and sign a written informed consent.
PubMedID- 24486058 All patients with advanced nsclc, with the exclusion of pure squamous cell carcinoma in former or current smokers, should be tested for egfr mutations and alk rearrangements before decisions are made on first-line treatment.
PubMedID- 21487406 The poorer response of nsclc patients with squamous cell carcinoma to pemetrexed is thus thought to result from the higher level of ts expression in such tumours.
PubMedID- 24568487 In nsclc patients with initial treatment, squamous carcinoma and phase iii, there were significant differences in orr and dcr between the groups (p<0.05), while orr was significant in patients with adenocarcinoma, gp/tp and in phase iiia (p<0.05).
PubMedID- 21532835 nsclc, consisting mainly of adenocarcinoma, squamous cell and large cell carcinoma, accounts for almost 80% of lung cancer cases, whereas sclc is slightly more common and all known cases are due to cigarette smoking.
PubMedID- 20479645 The mean stk1 value of nsclc patients with squamous cell carcinoma was significantly higher as compared with adenocarcinoma type (p=0.024).
PubMedID- 19900214 nsclc is composed primarily of adenocarcinoma, squamous cell carcinoma and to a lesser extent large-cell lung cancer.
PubMedID- 20855974 Chemosensitivity to paclitaxel and six other chemotherapeutic agents was evaluated using the succinate dehydrogenase inhibition (sdi) method in 69 nsclc cases, consisting of 48 adenocarcinomas, 20 squamous cell carcinomas and 1 large cell carcinoma.
PubMedID- 22890830 Our measurement of serum markers of cancer indicated that nse, ca-125, and cya 21-1 levels were similar in nsclc patients with squamous cell carcinoma and adenocarcinoma.
PubMedID- 22357618 Hh pathway activity and expression of ptch1 and smo were significantly higher in squamous cell carcinomas compared with other nsclc histological types (gialmanidis et al., 2009).

Page: 1